Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) (TRANSCEND)

This open-label, Phase II trial (n=16) will assess the feasibility, tolerability, and preliminary efficacy of psilocybin (25mg) therapy for adults with chronic neuropathic pain and treatment-resistant depression (TRD).

The study, sponsored by the Centre for Addiction and Mental Health, aims to evaluate whether psilocybin can effectively alleviate both chronic pain and depression symptoms in individuals who have not responded well to other treatments.

Conducted by Dr. Muhammad Ishrat Husain, the trial will provide each participant with a single 25 mg dose of psilocybin, accompanied by supportive therapy.

Outcomes will be measured through various scales, including the Montgomery-Åsberg Depression Rating Scale and the Patient Reported Outcomes Measurement Information System for pain intensity and interference.

The trial is set to start in September 2024 and is expected to complete by September 2026.

Trial Details

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.

Trial Number NCT06518720

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.